News | August 27, 2021
Marksans announces US FDA approval for Acetaminophen Extended- Release tablets
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The company will manufacture the products at its US FDA approved oral dosage facility at Goa in India
The product will be available in 500 mg/2.5 mL and 1 g/5 mL vials
First results demonstrate favourable tolerability of TQL-1055 at all dose levels
The company recently raised US $ 2.25 million seed round and the app was CE-Certified as a medical device in Europe
The Evolut FX TAVR system is used for treatment of symptomatic severe aortic stenosis and it has features that enhance ease-of-use and predictable valve deployment
Goal of providing 12-month internship opportunities for qualified students
First and only therapy approved by the FDA for the treatment of pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis
Trillium’s portfolio includes biologics that are designed to enhance the ability of patients’ innate immune system to detect and destroy cancer cells
This year, the company plans to set up more than 200 labs and 3000 collection centres across the world and has ended FY 21 with a revenue of Rs 800 crores
XELJANZ is the first and only Janus kinase (JAK) inhibitor approved in Europe for the treatment of polyarticular JIA and juvenile PsA and has received regulatory approval in four indications in the European Union, the most of any JAK inhibitor
Subscribe To Our Newsletter & Stay Updated
